PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14622157-5	2003	Priming with either SKF38393 or quinpirole further increased GAD67 mRNA in enkephalin (-) and (+) neurons, however, while SKF38393 produced a high and unbalanced activation toward enkephalin (-) neurons, after quinpirole the increase was of low intensity and similar in the two pathways.	Quinpirole	32-42	proenkephalin	Rattus norvegicus	75-85	
14622157-5	2003	Priming with either SKF38393 or quinpirole further increased GAD67 mRNA in enkephalin (-) and (+) neurons, however, while SKF38393 produced a high and unbalanced activation toward enkephalin (-) neurons, after quinpirole the increase was of low intensity and similar in the two pathways.	Quinpirole	32-42	proenkephalin	Rattus norvegicus	180-190	
7534387-2	1994	Subsequent systemic administration of either the D2 dopamine agonist, quinpirole, or the muscarinic antagonist, scopolamine, results in the reduction of the lesion-induced elevation in striatal enkephalin messenger RNA.	Quinpirole	70-80	proenkephalin	Rattus norvegicus	194-204	
7534387-4	1994	To dissociate these possibilities, we have compared the effects of systemic and central administration of quinpirole and scopolamine on striatal enkephalin and substance P messenger RNAs using in situ hybridization histochemistry.	Quinpirole	106-116	proenkephalin	Rattus norvegicus	145-155	
7534387-5	1994	Systemic administration of both quinpirole and scopolamine blocked the elevation of striatal enkephalin messenger RNA normally observed in 6-hydroxydopamine-lesioned rats.	Quinpirole	32-42	proenkephalin	Rattus norvegicus	93-103	
7534387-8	1994	In contrast to systemic administration, intraventricular and intrastriatal infusion of quinpirole but not scopolamine prevented the lesion-induced change in striatal enkephalin messenger RNA.	Quinpirole	87-97	proenkephalin	Rattus norvegicus	166-176	
7534387-10	1994	Together, these data suggest that changes in D2 receptor activation directly in the striatum are responsible for the effects of quinpirole on enkephalin messenger RNA.	Quinpirole	128-138	proenkephalin	Rattus norvegicus	142-152	
1356580-8	1992	Continuous quinpirole elevated somatostatin and neuropeptide Y levels (up 43% and 33%, respectively), but reduced the lesion-induced increases in both neurotensin (down 51%) and enkephalin (down 24%) content.	Quinpirole	11-21	proenkephalin	Rattus norvegicus	178-188	
1673340-5	1991	Quinpirole decreased [Met5]- and [Leu5]-enkephalin levels, while sulpiride decreased [Leu5]-enkephalin levels alone.	Quinpirole	0-10	proenkephalin	Rattus norvegicus	40-50